

CITATION REPORT

List of articles citing

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

DOI: 10.1186/1471-230x-3-19
BMC Gastroenterology, 2003, 3, 19.

Source: <https://exaly.com/paper-pdf/35221772/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
226	Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. 2004 , 10, 7629-36		104
225	An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. 2004 , 68, 1003-15		163
224	Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines. 2004 , 1030, 219-29		17
223	Molecular mechanisms of echinocystic acid-induced apoptosis in HepG2 cells. 2004 , 321, 539-46		36
222	Alcohol and liver cancer. 2005 , 35, 195-203		119
221	Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. 2005 , 90, 249-59		19
220	MAP Kinase Pathways in the Control of Hepatocyte Growth, Metabolism and Survival. 2005 , 223-238		7
219	Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. 2005 , 65, 6780-8		75
218	Integration of Ras subeffector signaling in TGF-beta mediated late stage hepatocarcinogenesis. 2005 , 26, 931-42		42
217	Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. 2005 , 69, 342-7		47
216	Insulin-like growth factor-I stimulates H4II rat hepatoma cell proliferation: dominant role of PI-3K/Akt signaling. 2006 , 312, 1142-52		19
215	The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. 2006 , 8, 1-8		56
214	Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. 2006 , 66, 11851-8		1132
213	Orchiectomy reduces hepatotumorigenesis of H-ras12V transgenic mice via the MAPK pathway. <i>Life Sciences</i> , 2006 , 79, 1974-80	6.8	8
212	MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. 2006 , 86, 687-96		33
211	Pleiotropic effects of PI-3Kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis. 2006 , 1090, 1-17		29
210	Hepatocellular carcinoma: molecular biology and therapy. 2006 , 33, S79-83		35

209	Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. 2006 , 66, 2048-58	136
208	Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. 2006 , 12, 4306-14	87
207	Requirement for Map2k1 (Mek1) in extra-embryonic ectoderm during placentogenesis. 2006 , 133, 3429-40	64
206	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. 2006 , 24, 4293-300	1002
205	Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. 2007 , 67, 8301-6	28
204	Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. 2007 , 3, 545-56	7
203	Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. 2007 , 6, 138-46	127
202	AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. 2007 , 6, 2468-76	38
201	MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. 2007 , 212, 526-36	28
200	Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. 2008 , 99, 159-65	137
199	Growth factors as therapeutic targets in HCC. 2008 , 67, 8-15	28
198	RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. 2008 , 27, 5315-25	65
197	Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. 2008 , 591, 13-20	48
196	Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. 2008 , 147, 23-33	44
195	Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. 2008 , 48, 83-90	250
194	Molecular Targeting in Hepatocellular Carcinoma. 2008 , 165-210	1
193	Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. 2008 , 68, 4192-200	90
192	Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. 2008 , 14, 5124-30	136

191	Sorafenib in hepatocellular carcinoma: separating the hype from the hope. 2008 , 26, 5845-8		26
190	Characterization of gametogenetin 1 (GGN1) and its potential role in male fertility through the interaction with the ion channel regulator, cysteine-rich secretory protein 2 (CRISP2) in the sperm tail. 2008 , 135, 751-9		39
189	Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest. 2008 , 68, 6743-51		29
188	Sorafenib for the treatment of unresectable hepatocellular carcinoma. 2008 , 2, 779-88		33
187	Sorafenib, a systemic therapy for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2008 , 7, 46-51	3.1	25
186	Sorafenib in Hepatocellular Carcinoma. 2009 , 1, CMT.S2314		
185	Emerging Raf inhibitors. 2009 , 14, 633-48		30
184	Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. 2009 , 329, 1063-70		32
183	Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? 2009 , 7, 42		10
182	RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. 2009 , 13, 1371-80		113
181	Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 2009 , 13, 2673-2683		104
180	CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. 2009 , 49, 1277-86		79
179	RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo. 2010 , 126, 1367-77		28
178	Management of advanced hepatocellular carcinoma in the era of targeted therapy. 2009 , 29, 10-7		58
177	Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. 2009 , 45, 579-87		65
176	A diet rich in cocoa attenuates N-nitrosodiethylamine-induced liver injury in rats. 2009 , 47, 2499-506		39
175	Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. 2009 , 28, 65		42
174	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. 2009 , 10, 25-34		4161

173	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. 2009 , 43, 489-95	125
172	Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. 2010 , 17, 120-9	32
171	Sorafenib in hepatocellular carcinoma. 2010 , 71, 451-6	13
170	Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. 2010 , 15, 242-55	28
169	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. 2010 , 45, 794-807	50
168	Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. 2010 , 5, 59-63	38
167	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. 2010 , 134, 237-50	115
166	AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. 2010 , 116, 1315-25	36
165	Transcriptional and post-transcriptional control of DNA methyltransferase 3B is regulated by phosphatidylinositol 3 kinase/Akt pathway in human hepatocellular carcinoma cell lines. 2010 , 111, 158-67	18
164	The role of signaling pathways in the development and treatment of hepatocellular carcinoma. 2010 , 29, 4989-5005	647
163	hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. 2010 , 70, 8077-87	130
162	Developing better treatments in hepatocellular carcinoma. 2010 , 4, 551-60	20
161	Emerging MEK inhibitors. 2010 , 15, 203-23	50
160	AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). 2010 , 52, 79-87	74
159	Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. 2010 , 19, 663-72	20
158	An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. 2011 , 20, 1039-45	8
157	Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. 2011 , 41, 296-302	60
156	Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. 2011 , 37, 513-20	40

155	EGF receptor inhibitors for hepatocellular carcinoma. 2011 , 34-43	
154	Proteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells. 2011 , 137, 965-73	15
153	Role of methionine adenosyltransferase genes in hepatocarcinogenesis. 2011 , 3, 1480-97	26
152	The molecular pathogenesis and clinical implications of hepatocellular carcinoma. 2011 , 2011, 818672	19
151	Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa ⁻ /p53 ^{+/-} mice upon exposure to benzo[a]pyrene. 2011 , 123, 123-32	21
150	Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. 2011 , 29, 289-302	30
149	The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. 2012 , 7, e51916	32
148	Retinoic acid induced 16 enhances tumorigenesis and serves as a novel tumor marker for hepatocellular carcinoma. 2012 , 33, 2578-85	12
147	The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control. 2012 , 2012, 328372	33
146	Suppression of the hypoxia inducible factor-1 function by redistributing the aryl hydrocarbon receptor nuclear translocator from nucleus to cytoplasm. 2012 , 320, 111-21	6
145	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. 2012 , 48, 1452-65	197
144	Pathways and targets in hepatocellular carcinoma. 2012 , 12, 1347-57	51
143	Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. 2012 , 39, 493-502	67
142	Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1. 2012 , 143, 787-798.e13	34
141	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 2012 , 3, 236-60	138
140	Management of hepatocellular carcinoma: beyond sorafenib. 2012 , 14, 257-66	22
139	Release of overexpressed CypB activates ERK signaling through CD147 binding for hepatoma cell resistance to oxidative stress. 2012 , 17, 784-96	23
138	Targeted therapy of hepatocellular carcinoma: present and future. 2012 , 27, 862-72	63

137	Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. 2012 , 295, 423-31	24
136	RNA interference targeting human integrin β suppresses the metastasis potential of hepatocellular carcinoma cells. 2013 , 18, 52	11
135	The evolving landscape of therapeutic drug development for hepatocellular carcinoma. 2013 , 36, 605-15	7
134	Hepatocellular carcinoma biology. 2013 , 190, 1-20	41
133	Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. 2013 , 14, 181-90	70
132	Systemic therapies in hepatocellular carcinoma: present and future. 2013 , 9, 1533-48	38
131	Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. 2013 , 8, e54111	26
130	New agents on the horizon in hepatocellular carcinoma. 2013 , 5, 41-50	19
129	IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. 2013 , 304, G328-36	43
128	S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway. 2013 , 42, 1001-10	33
127	Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. 2013 , 57, 678-88	51
126	Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. 2013 , 8, e65726	30
125	[Current status of molecular targeted therapies in hepatocellular carcinoma]. 2013 , 61, 136-46	4
124	Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. 2014 , 80, 680-4	13
123	Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. 2014 , 5, 5819-31	40
122	Hepatocellular carcinoma: systemic therapies and future perspectives. 2014 , 14, 1205-18	38
121	Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma. 2014 , 13, 377-85	14
120	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 2014 , 10, 285-304	11

119	Autophagy: A novel therapeutic target for hepatocarcinoma (Review). 2014 , 7, 1345-1351	25
118	Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. 2014 , 2014, 203693	58
117	A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. 2014 , 20, 5976-85	75
116	Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma. 2014 , 13, 216	66
115	Forecasting cell death dose-response from early signal transduction responses in vitro. 2014 , 140, 338-51	5
114	Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. 2014 , 13, 2352-60	113
113	MEK in cancer and cancer therapy. 2014 , 141, 160-71	174
112	Growth inhibition by pennogenyl saponins from <i>Rhizoma paridis</i> on hepatoma xenografts in nude mice. 2014 , 83, 39-44	20
111	Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. 2014 , 8, 1249-1254	28
110	Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. 2015 , 62, 1791-803	43
109	Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. 2015 , 7, 787-98	119
108	Interstitial Fluid Flow Increases Hepatocellular Carcinoma Cell Invasion through CXCR4/CXCL12 and MEK/ERK Signaling. 2015 , 10, e0142337	26
107	Gene Network Analysis of Glucose Linked Signaling Pathways and Their Role in Human Hepatocellular Carcinoma Cell Growth and Survival in HuH7 and HepG2 Cell Lines. 2015 , 2015, 821761	21
106	FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma. 2015 , 458, 313-20	34
105	Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression. 2015 , 62, 1278-86	27
104	MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. 2015 , 9, 993-1003	23
103	S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways. 2015 , 334, 228-38	46
102	An integrative approach for a network based meta-analysis of viral RNAi screens. 2015 , 10, 6	6

101	The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. 2015 , 45, 609-23	133
100	Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling. 2015 , 137, 104-15	27
99	OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. 2016 , 31, 1215-23	16
98	The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. 2016 , 12, 3045-3050	139
97	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. 2016 , 17, 1923-36	12
96	FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. 2016 , 48, 1492-1497	12
95	Heterogeneity of Hepatocellular Carcinoma. 2016 , 371-398	
94	The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition. 2016 , 37, 11311-20	4
93	The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. 2016 , 575, 66-70	43
92	Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. 2017 , 88, 395-402	14
91	Metabolic Pathway Inhibition in Liver Cancer. 2017 , 22, 237-244	14
90	Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. 2017 , 22, 191-200	3
89	Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. 2017 , 315, 90-101	40
88	Ectopic overexpression of filamin C scaffolds MEK1/2 and ERK1/2 to promote the progression of human hepatocellular carcinoma. 2017 , 388, 167-176	17
87	Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles. 2017 , 15, 380-386	5
86	Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma. 2017 , 24, 1073274817729243	24
85	Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. 2017 , 13, 904	47
84	Beta-Catenin and the Survival of Hepatocytes. 2017 , 87-132	

83	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?. 2017 , 18, 35-44	16
82	Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. 2017 , 12, 1-10	65
81	Disrupting CCT- β tubulin selectively kills CCT- β overexpressed cancer cells through MAPKs activation. 2017 , 8, e3052	8
80	Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. 2017 , 2017, 5198798	25
79	Implication of the Hedgehog pathway in hepatocellular carcinoma. 2017 , 23, 4330-4340	33
78	The role of autophagy in hepatocellular carcinoma: friend or foe. 2017 , 8, 57707-57722	95
77	Saponins isolated from <i>Schizocapsa plantaginea</i> inhibit human hepatocellular carcinoma cell growth in vivo and in vitro via mitogen-activated protein kinase signaling. 2018 , 16, 29-40	3
76	The deubiquitinase USP21 stabilizes MEK2 to promote tumor growth. 2018 , 9, 482	29
75	<i>Antrodia cinnamomea</i> boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. 2018 , 8, 12914	10
74	miR-330-3p suppresses liver cancer cell migration by targeting MAP2K1. 2019 , 18, 314-320	18
73	Long non-coding RNAs (CASC2 and TUG1) in hepatocellular carcinoma: Clinical significance. 2019 , 21, e3112	14
72	Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells. 2019 , 34, 853-860	13
71	Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression. 2019 , 110, 1573-1586	11
70	ZCCHC13-mediated induction of human liver cancer is associated with the modulation of DNA methylation and the AKT/ERK signaling pathway. 2019 , 17, 108	9
69	Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma. 2019 , 11,	7
68	Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. 2019 , 9, 19095	26
67	Development and Validation of Nomograms Based on Gamma-Glutamyl Transpeptidase to Platelet Ratio for Hepatocellular Carcinoma Patients Reveal Novel Prognostic Value and the Ratio Is Negatively Correlated With P38MAPK Expression. <i>Frontiers in Oncology</i> , 2020 , 10, 548744	5.3 6
66	Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer. 2020 , 13, 10499-10513	5

65	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. 2020 , 9, 7453-7459	4
64	Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. 2020 , 21,	7
63	14,15-Ethanedithiol inhibits HepG2 cell proliferation and migration through p38MAPK pathway. 2020 , 72, 1165-1175	1
62	Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. 2020 , 12,	91
61	A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. 2020 , 85, 593-604	13
60	Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. 2020 , 41, 1609-1620	18
59	Signaling pathways in hepatocellular carcinoma. 2021 , 149, 63-101	8
58	Diabetes induced renal complications by leukocyte activation of nuclear factor κ B and its regulated genes expression. 2021 , 28, 541-549	3
57	A model of seven immune checkpoint-related genes predicting overall survival for head and neck squamous cell carcinoma. 2021 , 278, 3467-3477	7
56	Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). 2021 , 152, 329-381	0
55	PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. 2021 , 6, 86	5
54	Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the in Suppressing Hepatocellular Carcinoma. 2021 , 12, 618522	4
53	Manuka honey enhanced sensitivity of HepG2, hepatocellular carcinoma cells, for Doxorubicin and induced apoptosis through inhibition of Wnt/ β -catenin and ERK1/2. 2021 , 54, 16	8
52	Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. 2021 , 9, 64	3
51	Knockout of Hepatocyte Growth Factor by CRISPR/Cas9 System Induces Apoptosis in Hepatocellular Carcinoma Cells. 2021 , 11,	0
50	Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF- κ B and VEGF/VEGFR2 signaling pathways. 2021 , 48, 7233-7242	0
49	Proteinase-activated receptors (PARs) and calcium signaling in cancer. 2012 , 740, 979-1000	14
48	Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. 2011 , 34, 125-9	9

47	EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome. 2013 , 8, e74313	32
46	miTALOS v2: Analyzing Tissue Specific microRNA Function. 2016 , 11, e0151771	47
45	Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma. 2011 , 2, 195-204	9
44	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 2011 , 3, 192-222	437
43	Investigating the mechanism of hepatocellular carcinoma progression by constructing genetic and epigenetic networks using NGS data identification and big database mining method. 2016 , 7, 79453-79473	13
42	The cyclin-like protein, SPY1, regulates the ER and ERK1/2 pathways promoting tamoxifen resistance. 2017 , 8, 23337-23352	7
41	Evolution of systemic therapy of advanced hepatocellular carcinoma. 2008 , 14, 6437-41	50
40	Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. 2012 , 18, 6005-17	36
39	Molecular targeted therapy for hepatocellular carcinoma: current and future. 2013 , 19, 6144-55	60
38	Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. 2014 , 20, 486-97	15
37	Current approach in the treatment of hepatocellular carcinoma. 2010 , 2, 348-59	69
36	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?. 2016 , 7, 242-55	10
35	Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. 2013 , 14, 7367-9	26
34	Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. 2014 , 15, 3151-6	5
33	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. 2021 , 13,	6
32	The Efficacy of Sorafenib for Patients With Advanced Hepatocellular Carcinoma. 2007 , 13, 576	
31	Chemotherapy of Liver Tumors. 2007 , 1298-1311	
30	Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma. 2007 , 211-242	

29	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma. 2009 , 15, 227		1
28	Targeted Therapies in Hepatocellular Carcinoma. 2015 , 137-145		
27	Targeted Therapies for Hepatocellular Carcinoma. 2016 , 513-529		
26	Hepatocellular Carcinoma. 2018 , 668-692.e9		1
25	The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound.. <i>Translational Cancer Research</i> , 2019 , 8, 1224-1232	0.3	0
24	Crosstalk of Molecular Signaling in Hepatocellular Carcinoma. 2020 , 85-94		0
23	LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway. <i>Bioscience Reports</i> , 2020 , 40,	4.1	3
22	Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, S85-9		
21	Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 2382-91	1.4	14
20	RKIP suppresses the proliferation and invasion of choriocarcinoma cells through inhibiting the MAPK signaling pathway. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 22183-90		4
19	[The targets research of non-small cell lung cancer targeted therapy]. <i>Chinese Journal of Lung Cancer</i> , 2013 , 16, 107-13	0.6	0
18	B-RAF PROTEIN IMMUNOEXPRESSION IN HEPATOCELLULAR CARCINOMA DUE TO HEPATITIS C VIRUS RELATED CIRRHOSIS.. <i>Arquivos De Gastroenterologia</i> , 2021 , 58, 419-423	1.3	
17	Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing.. <i>Annals of Hepatology</i> , 2022 , 100677	3.1	1
16	Nanoemulsion. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2022 , 307-329	0.2	
15	Proliferative signaling pathways in hepatocellular carcinoma. 2022 , 255-271		
14	Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach. 2022 , 83-103		
13	Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options. 2022 , 337-355		
12	DataSheet_1.docx. 2020 ,		

11 DataSheet_2.csv. **2020**,

10	Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. <i>Genes and Diseases</i> , 2022 ,	6.6	o
9	Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway. <i>Stem Cell Research and Therapy</i> , 2022 , 13,	8.3	o
8	Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF- κ B pathways and LncRNA-AF085935/GPC3 axis. <i>Life Sciences</i> , 2022 , 303, 120675	6.8	o
7	Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy. <i>Frontiers in Oncology</i> , 12,	5.3	
6	ERK2 signaling regulates cell-cell adhesion of epithelial cells and enhances growth factor-induced cell scattering. 2022 , 110431		o
5	Wnt/ β -catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review. 2022 , 155, 113713		o
4	CLEFMA Induces the Apoptosis of Oral Squamous Carcinoma Cells through the Regulation of the P38/HO-1 Signalling Pathway. 2022 , 14, 5519		o
3	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead. A Systematic Review. 2022 , 23, 14117		1
2	Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways. 2022 , 110329		o
1	Comparison of anti-tumor activities and underlying mechanisms of glucuronomannan oligosaccharides and its sulfated derivatives on the hepatocarcinoma Huh7.5 cells. 2023 , 652, 103-111		o